|
| Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy |
|
https://doi.org/10.18632/oncotarget.26916
Jéan-Pierre Gérard, Nicolas Barbet, Karen Benezery
|
| 3431-3432 |
|
| circPSMC3: ceRNA and tumor suppressor |
|
https://doi.org/10.18632/oncotarget.26953
Chen Lu, Dawei Rong, Weiwei Tang
|
| 3433-3434 |
|
| Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism |
|
https://doi.org/10.18632/oncotarget.26952
Mujib Ullah, Asma Akbar, Nathan Norton Ng, Waldo Concepcion, Avnesh S. Thakor
|
| 3435-3450 |
|
| Endotoxin tolerance modulates TREG and TH17 lymphocytes protecting septic mice |
|
https://doi.org/10.18632/oncotarget.26919
|
| 3451-3461 |
|
| The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells |
|
https://doi.org/10.18632/oncotarget.26877
Kathryn Clarke, Christine Young, Fabio Liberante, Mary-Frances McMullin, Alexander Thompson, Ken Mills
|
| 3462-3471 |
|
| Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes |
|
https://doi.org/10.18632/oncotarget.26930
Faruck L. Hakkim, Hamid A. Bakshi, Shabia Khan, Mohamad Nasef, Rabia Farzand, Smitha Sam, Luay Rashan, Mohammed S. Al-Baloshi, Sidgi Syed Anwar Abdo Hasson, Ali Al Jabri, Paul A. McCarron, Murtaza M. Tambuwala
|
| 3472-3490 |
|
| IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways |
|
https://doi.org/10.18632/oncotarget.26834
István Gyurján, Sandra Rosskopf, Johana A. Luna Coronell, Daniela Muhr, Christian Singer, Andreas Weinhäusel
|
| 3491-3505 |
|
| Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas |
|
https://doi.org/10.18632/oncotarget.26941
Joshua Loewenstern, John Rutland, Corey Gill, Hanane Arib, Margaret Pain, Melissa Umphlett, Yayoi Kinoshita, Russell McBride, Michael Donovan, Robert Sebra, Joshua Bederson, Mary Fowkes, Raj Shrivastava
|
| 3506-3517 |
|
| Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators |
|
https://doi.org/10.18632/oncotarget.26943
Gang Cheng, Jacek Zielonka, Micael Hardy, Olivier Ouari, Christopher R. Chitambar, Michael B. Dwinell, Balaraman Kalyanaraman
|
| 3518-3532 |
|
| Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options |
|
https://doi.org/10.18632/oncotarget.26947
Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, Sanghoon Lee, Wei Zhao, Yong Fang, Yiling Lu, Ken Chen, Pedro Ramirez, Michael Frumovitz, Larissa Meyer, Nicole D. Fleming, Anil K. Sood, Robert L. Coleman, Gordon B. Mills, Shannon N. Westin
|
| 3533-3546 |
|
| In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile |
|
https://doi.org/10.18632/oncotarget.26949
Shuhei Suzuki, Masahiro Yamamoto, Keita Togashi, Tomomi Sanomachi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka, Masashi Okada
|
| 3547-3558 |
|
| Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model |
|
https://doi.org/10.18632/oncotarget.26894
Rasha H. Dosh, Nicola Jordan-Mahy, Christopher Sammon, Christine Le Maitre
|
| 3559-3575 |
|
| Correction: The role of substance P in epilepsy and seizure disorders |
|
https://doi.org/10.18632/oncotarget.26991
Xue Feng Wang, Tong Tong Ge, Jie Fan, Wei Yang, Li Bingjin, Ran Ji Cui
|
| 3576-3576 |
|
| Correction: Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress |
|
https://doi.org/10.18632/oncotarget.26997
Yu-Chin Lin, Meng-Hsuan Wu, Tzu-Tang Wei, Yun-Chieh Lin, Wen-Chih Huang, Liang-Yu Huang, Yi-Ting Lin, Ching-Chow Chen
|
| 3577-3578 |
